Grant Received from the Bill & Melinda Gates Foundation to Fund Development of Affordable TherapeuticsJUPITER, Fla., Nov. 21, ...

No writing assistance was utilized in the production of this manuscript. Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA).

Dyadic International has secured a $3 million grant from the Bill & Melinda Gates Foundation to develop cost-effectiv ...

With several high-profile manufacturing outlays already in the books in Europe this year, Sanofi is returning to the bloc in ...

A Golden Gate-based dual-expression vector enables rapid screening, which facilitates efficient isolation of high-affinity cross-reactive antibodies for therapeutic or diagnostic use and provides a ...

Dyadic international was awarded a $3 million grant from the Bill & Melinda Gates Foundation to fund the development of ...

GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of ...

Dyadic International (DYAI) announced that it has been awarded a $3M grant from the Gates Foundation for the cell line development of monoclonal antibodies targeting respiratory syncytial virus and ...

Zenyaku Kogyo receives Japanese approval for anti-CD20 monoclonal antibody, Rituxan to treat chronic ITP in children: Tokyo Saturday, November 23, 2024, 10:00 Hrs [IST] Zenyaku Ko ...

Adagene Inc. (NASDAQ:ADAG – Get Free Report) was the target of a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 1,500 shares, a ...